The aim of this study was to illustrate the initial subclinical drug-induced liver injury and the associated adaptive immune response by monitoring for the changes in plasma IL-2, IL-10, and some cytochrome P450 activity during chronic administration of nevirapine (NVP), isoniazid (INH), and paracetamol (PAR) in rats without clinical hepatotoxicity. Male Sprague-Dawley (SD) rats were divided in...

•Routine 2-week liver tests were evaluated in a 1247 patient cohort treated for TB. •Anti-tuberculous therapy (ATT) led to drug-induced injury (DILI) 8.3%. •Risk of late TB-DILI increased 2.2-fold every 30 U/L rise pre-treatment ALT. 2.1-fold gradient ALT change. Objective Tuberculosis Drug Induced Liver Injury (TB-DILI) is common and potentially severe complication associated with anti-tubercu...

The article deals with a review of the current literature on clinical use hepatoprotectors in drug-induced liver injury. was searched Scopus, Web Science, PubMed and other databases. Risk factors, pathogenetic mechanisms li­ver damage, international diagnostic criteria treatment for injuries are considered. Clinical pharmacological approaches to choice management injury substantiated. positive ...

Drug-induced liver diseases (DILD) are clinico-pathologic patterns of liver injury caused by drugs or other foreign compounds. Steatohepatitis is a rare form of DILD, and drugs account for fewer than 2% of non-alcoholic steatohepatitis (NASH). Drugs known to be capable of inducing steatosis and steatohepatitis can be divided into three broad groups: those that cause steatosis and steatohepatiti...